Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.43
+0.13 (1.71%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 10.8, with a low estimate of 8.00 and a high estimate of 12. The average target predicts an increase of 45.45% from the current stock price of 7.43.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +48.15% | Mar 3, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $9 → $12 | Hold → Buy | Upgrades | $9 → $12 | +61.62% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +48.15% | Nov 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +61.62% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +21.21% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
3.09B
from 2.79B
Increased by 10.49%
Revenue Next Year
3.30B
from 3.09B
Increased by 7.00%
EPS This Year
0.69
from -0.38
EPS Next Year
0.82
from 0.69
Increased by 17.65%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 3.2B | 3.5B | 3.8B |
| Avg | 3.1B | 3.3B | 3.5B |
| Low | 2.9B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.6% | 12.5% | 15.3% |
| Avg | 10.5% | 7.0% | 6.9% |
| Low | 5.3% | -0.5% | -2.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.72 | 0.86 | 1.14 |
| Avg | 0.69 | 0.82 | 1.02 |
| Low | 0.66 | 0.76 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 24.1% | 40.3% |
| Avg | - | 17.6% | 25.0% |
| Low | - | 10.2% | 9.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.